7
Views
8
CrossRef citations to date
0
Altmetric
Original Article

Dose-dependent effect of niceritrol on plasma lipoprotein-a

, , , , , , , , , , , , , , , , & show all
Pages 359-365 | Received 12 Sep 1995, Accepted 20 Feb 1996, Published online: 08 Jul 2009

References

  • Canner P L, Berge K G, Wenger N K, Stamler J, Friedman L, Prineas R J, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. JACC 1986; 8: 1245–55
  • Cashin-Hemphill L, Mack W J, Pogoda J M, Sanmarco M E, Azen S P, Blankenhorn D H. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. J Am Med Assoc 1990; 264: 3013–17
  • National Cholesterol Education Program (NCEP) Expert Panel. Summary of the second report on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). J Am Med Assoc 1993; 269: 3015–23
  • Carlson L A, Haquten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989; 226: 271–6
  • Warnick G R, Albers J J. Heparin-Mn2+ quantitation of high density lipoprotein cholesterol: an ultrafiltration procedure for lipemic samples. Clin Chem 1978; 24: 900–4
  • Friedewald W T, Levy R I, Fredrickson D S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502
  • Berg K. A new serum type system in man—the Lp system. Acta Pathol Microbiol Scand 1963; 59: 369–82
  • Dahlen +9999 Lipoprotein (a) in relation to atherosclerotic diseases. Recent aspects of diagnosis and treatment of lipoprotein disorders. Impact on prevention of atherosclerotic disease, K Widhalm, H K Naito. Liss, New York 1988; 27–36
  • Hiraga T, Kobayashi T, Okubo M, Nakanishi K, Sugimoto T, Ohashi Y, et al. Prospective study of lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes. Diabetes Care 1995; 18: 241–4
  • Terres W, Tatsis E, Pfalzer B, Beil F U, Beisiegel U, Hamm C W. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Circulation 1995; 91: 948–50
  • Desmarais R L, Sarembock I J, Ayers C R, Vernon S M, Powers E R, Gimple L W. Elevated serum lipoprotein (a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995; 91: 1403–9
  • Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, et al. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Goettingen risk incidence and prevalence study (GRIPS). Eur J Clin Invest 1994; 24: 444–53
  • Schaefer E J, Lamon-Fava S, Jenner J L, McNamara M T, Ordovas J M, Davis C E, et al. Lipoprotein(a) levels and risk of coronary heart disease in men: the lipid research clinics' coronary primary prevention trial. J Am Med Assoc 1994; 271: 999–1003
  • Sano R, Fujino A, Kobayashi M, Shimazu H, Yahata Y, Ogyu A. Effects of ordinary dose of niceritrol on serum concentration of lipoprotein(a). Clin Rep 1991; 23: 2319–23
  • Vessby B, Kostner G, Lithell H, Thomis J. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). Atherosclerosis 1982; 44: 61–71
  • Kostner G M, Gavish D, Leopold B, Bolzano K, Weintraub M S, Breslow J L. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989; 80: 1313–19

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.